Celcuity (CELC)
Develops and prepares to commercialize gedatolisib therapies for advanced breast and prostate cancers.
$84.23
vs last close+0.23 (+0.27%)
Something off on this page? Send us feedback.
Next report
Nov 11, 26
in 50 days
EPS estimate
−$1.44
Revenue estimate
$4.0M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.85−$0.86−$1.04−$0.92−$0.97−$0.97−$1.44Pending
Estimate−$0.72−$0.95−$0.90−$1.02−$1.06−$1.04−$1.16−$1.44
Surprise−18.1%+9.5%−15.6%+9.8%+8.5%+6.7%−24.1%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$121.3K—————$94.0KPending
Estimate————$1.3M$2.9M$4.4M$4.0M
Surprise——————−97.9%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2027 | $0.12 | — | — |
| Sep 2027 | −$0.30 | — | — |
| Jun 2027 | −$0.69 | — | — |
| Mar 2027 | −$0.99 | — | — |
| Dec 2026 | −$1.07 | — | — |
| Nov 2026 | −$1.44 | — | — |
| Aug 2026 | −$1.16 | −$1.44 | −24.1% |
| May 2026 | −$1.04 | −$0.97 | +6.7% |
| Mar 2026 | −$1.06 | −$0.97 | +8.5% |
| Nov 2025 | −$1.02 | −$0.92 | +9.8% |
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Feb 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Sep 2017 | |||
| Mar 2017 | |||
| Dec 2016 | |||
| Sep 2016 | |||
| Jun 2016 | |||
| Mar 2016 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2027 | $0.12 | — | — | $138.2M | — | — | — |
| Sep 2027 | −$0.30 | — | — | $98.2M | — | — | — |
| Jun 2027 | −$0.69 | — | — | $65.2M | — | — | — |
| Mar 2027 | −$0.99 | — | — | $44.5M | — | — | — |
| Dec 2026 | −$1.07 | — | — | $32.2M | — | — | — |
| Nov 11, 2026 | −$1.44 | — | — | $4.0M | — | — | — |
| Aug 13, 2026 | −$1.16 | −$1.44 | −24.1% | $4.4M | $94.0K | −97.9% | +6.2% |
| May 14, 2026 | −$1.04 | −$0.97 | +6.7% | $2.9M | — | — | +2.2% |
| Mar 25, 2026 | −$1.06 | −$0.97 | +8.5% | $1.3M | — | — | +4.2% |
| Nov 12, 2025 | −$1.02 | −$0.92 | +9.8% | — | — | — | +1.0% |
| Aug 14, 2025 | |||||||
| May 14, 2025 | |||||||
| Mar 31, 2025 | |||||||
| Nov 14, 2024 | |||||||
| Aug 14, 2024 | |||||||
| May 15, 2024 | |||||||
| Mar 27, 2024 | |||||||
| Nov 13, 2023 | |||||||
| Aug 10, 2023 | |||||||
| May 15, 2023 | |||||||
| Mar 23, 2023 | |||||||
| Nov 10, 2022 | |||||||
| Aug 11, 2022 | |||||||
| May 16, 2022 | |||||||
| Mar 23, 2022 | |||||||
| Nov 8, 2021 | |||||||
| Aug 9, 2021 | |||||||
| May 10, 2021 | |||||||
| Feb 16, 2021 | |||||||
| Nov 9, 2020 | |||||||
| Aug 10, 2020 | |||||||
| May 7, 2020 | |||||||
| Mar 12, 2020 | |||||||
| Nov 7, 2019 | |||||||
| Aug 8, 2019 | |||||||
| May 7, 2019 | |||||||
| Feb 26, 2019 | |||||||
| Nov 13, 2018 | |||||||
| Aug 9, 2018 | |||||||
| May 14, 2018 | |||||||
| Mar 15, 2018 | |||||||
| Nov 13, 2017 | |||||||
| Sep 20, 2017 | |||||||
| Mar 31, 2017 | |||||||
| Dec 31, 2016 | |||||||
| Sep 30, 2016 | |||||||
| Jun 30, 2016 | |||||||
| Mar 31, 2016 |